Laryngeal squamous cell carcinoma
MONDO:0005595A squamous cell carcinoma that arises from the larynx. It is the most common histologic type of laryngeal carcinoma. It can arise from the glottis, supraglottic area, or it can be transglottic. Glottic squamous cell carcinoma is the most frequent laryngeal carcinoma in the United States. The symptoms, clinical behavior and the prognosis depend on the site of origin within the larynx.
Also known as: epidermoid carcinoma of larynx, epidermoid carcinoma of the larynx, laryngeal epidermoid carcinoma, laryngeal squamous cell carcinoma, laryngeal throat squamous cell cancer, larynx epidermoid carcinoma, larynx squamous cell carcinoma, squamous cell carcinoma of larynx
2925 clinical trials for this condition and its sub-types, 72 tagged with Laryngeal squamous cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Laryngeal squamous cell carcinoma
-
Glottis squamous cell carcinoma 5 trials
1 sub-type
- Glottis verrucous carcinoma 0 trials
-
Larynx verrucous carcinoma 2 trials
3 sub-types
- Glottis verrucous carcinoma 0 trials
- Subglottis verrucous carcinoma 0 trials
- Supraglottis verrucous carcinoma 0 trials
-
1 sub-type
- Supraglottis verrucous carcinoma 0 trials
-
Subglottis squamous cell carcinoma 0 trials
1 sub-type
- Subglottis verrucous carcinoma 0 trials
-
Experimental drug targets Hard-to-Treat cancers, but trial ends early
Disease control Stopped earlyThis study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was terminat…
Phase 2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Peptide vaccine shows promise in head and neck cancer trial
Disease control Stopped earlyThis study tested a peptide-based immunotherapy in 17 people with head and neck cancer who were scheduled for surgery. The goal was to see if the vaccine could boost the immune system's attack on cancer cells and to check for side effects. The trial was stopped early, but the res…
Phase 2 • Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC